Investigating clinical and laboratory findings and mortality rates among vaccinated and unvaccinated COVID-19 inpatients

M. Özsoy, S. Cesur, Ç. Ataman Hatipoğlu, Ş. Erdinç, Günay Tuncer Ertem, S. Kınıklı
{"title":"Investigating clinical and laboratory findings and mortality rates among vaccinated and unvaccinated COVID-19 inpatients","authors":"M. Özsoy, S. Cesur, Ç. Ataman Hatipoğlu, Ş. Erdinç, Günay Tuncer Ertem, S. Kınıklı","doi":"10.38053/acmj.1218224","DOIUrl":null,"url":null,"abstract":"Aim: COVID-19 is an important public health problem in world and Turkey. The present study aimed to compare the clinical and laboratory findings and mortality rates among vaccinated and unvaccinated COVID-19 inpatients.Material and Method: We included patients receiving inpatient treatment in COVID-19 wards of our hospital between April 25 and October 22, 2021. The patients were divided into two groups: those with and without the COVID-19 vaccine. We extracted patient information from anamnesis files and the hospital information system. Then, we recorded the patients’ epidemiological and laboratory findings and vaccination status. Patients with at least two doses of the COVID-19 vaccine were considered “vaccinated.” We performed Fisher’s exact test and Chi-square test to analyze the data. All statistical analyses were performed in SPSS, and a p-value <0.05 was accepted as statistically significant.Results: The study included 63 vaccinated and 83 unvaccinated patients. With a mean age of 71.4±12.3 years, thirty (47.6%) of the vaccinated patients were females, and 33 (52.3%) were males. Of the unvaccinated ones, 40 (48.1%) were females, while 43 (51.8%) were males (mean age=52.2±14.4 years). The mean age was significantly higher in the vaccinated group than in the unvaccinated group (p<0.01). While 82.5% of the vaccinated patients received two doses, 17.5% received three doses of the COVID vaccine. Besides, 95.3% of the patients received their first dose of inactivated vaccine (Sinovac, China) and 4.7% of an mRNA vaccine (BioNTech, Germany). We found that comorbidities were significantly more prevalent in the vaccinated group than in the unvaccinated group (44 (69.8%) vaccinated and 34 (40.9%) unvaccinated patients had a comorbid disease, p<0.01). Among the accompanying diseases, hypertension was significantly more prevalent in the vaccinated group than in the unvaccinated group (p<0.01). Considering their laboratory findings, the vaccinated patients had significantly higher leukocyte, troponin, and ferritin values than the unvaccinated patients (p=0.008). Consequently, five (57.9) of the vaccinated patients and 4 (4.8%) of the unvaccinated patients died (p=0.05). Conclusion: Similar mortality rates between our vaccinated and unvaccinated patients may be attributed to the fact that the vaccinated group was relatively older, had more comorbid diseases, and received their second dose after an average of 100.6 days following their first dose of inactivated vaccine. In conclusion, further clinical research involving more cases that received different COVID-19 vaccines is needed to uncover the factors affecting mortality and morbidity among vaccinated patients.","PeriodicalId":307693,"journal":{"name":"Anatolian Current Medical Journal","volume":"21 1","pages":"0"},"PeriodicalIF":0.0000,"publicationDate":"2023-01-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Anatolian Current Medical Journal","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.38053/acmj.1218224","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

Aim: COVID-19 is an important public health problem in world and Turkey. The present study aimed to compare the clinical and laboratory findings and mortality rates among vaccinated and unvaccinated COVID-19 inpatients.Material and Method: We included patients receiving inpatient treatment in COVID-19 wards of our hospital between April 25 and October 22, 2021. The patients were divided into two groups: those with and without the COVID-19 vaccine. We extracted patient information from anamnesis files and the hospital information system. Then, we recorded the patients’ epidemiological and laboratory findings and vaccination status. Patients with at least two doses of the COVID-19 vaccine were considered “vaccinated.” We performed Fisher’s exact test and Chi-square test to analyze the data. All statistical analyses were performed in SPSS, and a p-value <0.05 was accepted as statistically significant.Results: The study included 63 vaccinated and 83 unvaccinated patients. With a mean age of 71.4±12.3 years, thirty (47.6%) of the vaccinated patients were females, and 33 (52.3%) were males. Of the unvaccinated ones, 40 (48.1%) were females, while 43 (51.8%) were males (mean age=52.2±14.4 years). The mean age was significantly higher in the vaccinated group than in the unvaccinated group (p<0.01). While 82.5% of the vaccinated patients received two doses, 17.5% received three doses of the COVID vaccine. Besides, 95.3% of the patients received their first dose of inactivated vaccine (Sinovac, China) and 4.7% of an mRNA vaccine (BioNTech, Germany). We found that comorbidities were significantly more prevalent in the vaccinated group than in the unvaccinated group (44 (69.8%) vaccinated and 34 (40.9%) unvaccinated patients had a comorbid disease, p<0.01). Among the accompanying diseases, hypertension was significantly more prevalent in the vaccinated group than in the unvaccinated group (p<0.01). Considering their laboratory findings, the vaccinated patients had significantly higher leukocyte, troponin, and ferritin values than the unvaccinated patients (p=0.008). Consequently, five (57.9) of the vaccinated patients and 4 (4.8%) of the unvaccinated patients died (p=0.05). Conclusion: Similar mortality rates between our vaccinated and unvaccinated patients may be attributed to the fact that the vaccinated group was relatively older, had more comorbid diseases, and received their second dose after an average of 100.6 days following their first dose of inactivated vaccine. In conclusion, further clinical research involving more cases that received different COVID-19 vaccines is needed to uncover the factors affecting mortality and morbidity among vaccinated patients.
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
调查接种疫苗和未接种疫苗的COVID-19住院患者的临床和实验室结果以及死亡率
目的:2019冠状病毒病是世界和土耳其面临的重大公共卫生问题。本研究旨在比较接种疫苗和未接种疫苗的COVID-19住院患者的临床和实验室结果以及死亡率。材料与方法:纳入2021年4月25日至10月22日在我院COVID-19病房住院治疗的患者。这些患者被分为两组:接种和未接种COVID-19疫苗的患者。我们从记忆文件和医院信息系统中提取患者信息。然后,我们记录了患者的流行病学和实验室结果以及疫苗接种情况。至少接种了两剂新冠病毒疫苗的患者被视为“接种了疫苗”。我们采用Fisher精确检验和卡方检验对数据进行分析。所有统计分析均采用SPSS软件进行,以p值<0.05为差异有统计学意义。结果:该研究包括63名接种疫苗的患者和83名未接种疫苗的患者。平均年龄71.4±12.3岁,女性30例(47.6%),男性33例(52.3%)。未接种者中,女性40例(48.1%),男性43例(51.8%),平均年龄52.2±14.4岁。接种组的平均年龄显著高于未接种组(p<0.01)。82.5%的患者接种了两剂疫苗,17.5%的患者接种了三剂疫苗。此外,95.3%的患者接种了第一剂灭活疫苗(中国Sinovac), 4.7%的患者接种了mRNA疫苗(德国BioNTech)。我们发现,接种疫苗组的合并症明显高于未接种疫苗组(44例(69.8%)接种疫苗和34例(40.9%)未接种疫苗的患者有合并症,p<0.01)。在伴随疾病中,接种疫苗组高血压患病率明显高于未接种疫苗组(p<0.01)。考虑到他们的实验室结果,接种疫苗的患者的白细胞、肌钙蛋白和铁蛋白值明显高于未接种疫苗的患者(p=0.008)。接种疫苗者死亡5例(57.9%),未接种者死亡4例(4.8%)(p=0.05)。结论:接种疫苗和未接种疫苗的患者死亡率相似,可能是由于接种疫苗组年龄相对较大,有更多的合并症,并且在接种第一次灭活疫苗后平均100.6天接种第二次灭活疫苗。总之,需要进一步开展临床研究,纳入更多接种不同COVID-19疫苗的病例,以揭示影响接种疫苗患者死亡率和发病率的因素。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
自引率
0.00%
发文量
0
期刊最新文献
Pan-immune inflammation value as a biomarker in ankylosing spondilitis and associated with disease activity ChatGPT in medical writing: enhancing healthcare communication through artificial intelligence and human expertise Temporal alterations in P-wave electrocardiographic metrics post patent foramen ovale closure: a retrospective study Asymptomatic COVID-19 and structural changes in the brain Exploring the nexus: prevalence, risk factors, and clinical correlations of urinary tract infections in diabetes mellitus patients - a comprehensive retrospective analysis
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1